prikaz prve stranice dokumenta Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
  Preuzmi
PDF 1.57 MB
Znanstveni rad - Izvorni znanstveni rad
Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
International Journal of Cardiology, 301 (2020); 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035
Lucijanić, Marko; Jurin, Ivana; Jurin, Hrvoje; Lucijanić, Tomo; Starčević, Boris; Skelin, Marko; Glasnović, Anton; Ćatić, Jasmina; Jurišić, Anđela; Hadžibegović, Irzal

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Lucijanić, M., Jurin, I., Jurin, H., Lucijanić, T., Starčević, B., Skelin, M. ... Hadžibegović, I. (2020). Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. International Journal of Cardiology, 301., 90-95. doi: 10.1016/j.ijcard.2019.10.035

Lucijanić, Marko, et al. "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes." International Journal of Cardiology, vol. 301, 2020, str. 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035

Lucijanić, Marko, Ivana Jurin, Hrvoje Jurin, Tomo Lucijanić, Boris Starčević, Marko Skelin, Anton Glasnović, Jasmina Ćatić, Anđela Jurišić i Irzal Hadžibegović. "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes." International Journal of Cardiology 301 (2020): 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035

Lucijanić, M., et al. (2020) 'Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes', International Journal of Cardiology, 301, str. 90-95. doi: 10.1016/j.ijcard.2019.10.035

Lucijanić M, Jurin I, Jurin H, Lucijanić T, Starčević B, Skelin M, i sur.. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. International Journal of Cardiology [Internet]. 15.02.2020. [pristupljeno 24.12.2024.];301:90-95. doi: 10.1016/j.ijcard.2019.10.035

M. Lucijanić, et al., "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes", International Journal of Cardiology, vol. 301, str. 90-95, Veljača 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:866450. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:866450
Podaci o radu
Naslov (engleski)Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
AutorMarko Lucijanić
AutorIvana Jurin
AutorHrvoje Jurin
AutorTomo Lucijanić
MBZ: 18024
AutorBoris Starčević
AutorMarko Skelin
AutorAnton Glasnović
AutorJasmina Ćatić
AutorAnđela Jurišić
AutorIrzal Hadžibegović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA HISTOLOGIJU I EMBRIOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists about their efficacy in a population of obese/overweight patients. ----- Patients and methods: We retrospectively investigated a real-life cohort of 325 DOAC anticoagulated patients with atrial fibrillation [179 receiving dabigatran (55%), 74 apixaban (23%) and 72 rivaroxaban (22%)]. Patients were stratified according to the body mass index (BMI) into non-obese (233 with BMI <30 kg/m2), class I obesity (71 with BMI 30-34.9 kg/m2) and class II + obesity (21 with BMI ≥35 kg/m2). ----- Results: Patients with higher BMI receiving DOACs were more likely to experience stroke/systemic embolism sooner (P = 0.043), experience major bleeding sooner (P < 0.001) and have shorter time to composite event consisting of thrombosis, bleeding or death (P < 0.001) whereas there was no significant association with overall survival (P = 0.470). BMI was significantly associated with thrombosis but not bleeding among dabigatran treated patients, and significantly associated with bleeding but not thrombosis among patients treated with factor Xa inhibitors. Associations of higher thrombotic, bleeding and composite endpoint risks with higher BMI remained statistically significant in multivariate Cox regression models adjusted for age, gender, eGFR, CHA2DS2VASC and HAS-BLED. ----- Conclusion: Our findings indicate that obese patients receiving DOACs, especially ones with class II + obesity, might be under higher risks of stroke/bleeding depending on DOAC subtype. Loss of efficacy might be associated with dabigatran, whereas higher risk of major bleeding might be associated with factor Xa inhibitors.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaInternational Journal of Cardiology
Brojčani podacivol. 301, str. 90-95
p-ISSN0167-5273
e-ISSN1874-1754
DOIhttps://doi.org/10.1016/j.ijcard.2019.10.035
URN:NBNurn:nbn:hr:105:866450
Datum objave publikacije2020-02-15
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0167527319342603
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Datum isteka embarga: 2021-02-17
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-12-09 10:18:09